Group items tagged

The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections. Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients. NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection. Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan. "Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.

After I have finished playing some casino games, using my, Juicy Stakes Casino bonuses, I am hungry. What should I eat? A juicy steak (wink, wink)? Fried chicken? An Ingestible Pill? Wait, what? What is an ingestible pill? Is that a food or vitamin? Actually, it is neither. It is new technology developed by Pfizer. Pfizer is the pharmaceutical company that gave us the COVID vaccines that do not provide lifetime immunity to COVID or even prevent you from getting it in the short term. Pfizer is also the company that created the COVID medicine Paxlovid, which cause Biden to get a rebound COVID right after he supposedly recovered from COVID. Ingestible Pills are a version of a digital pill A digital pill is also known as a smart pill or an ingestible sensor. It is a pharmaceutical dosage form that contains an ingestible sensor inside of a pill. The sensor begins transmitting medical data after it is consumed. This pill and its other related technology are considered Digital Medicine. The purpose of the sensor is to determine if a person is taking their medicine or they are not taking their medicine. In other words, is the patient complying with taking their medicine or are they not complying with taking their medicine?

Millions of people are frequently let down by the lottery's low chances of victory, despite its alluring promise of life-changing riches. Here comes the "Lottery Defeater software," which purports to change the game by giving players a strategic advantage.

In the competitive landscape of healthcare, strategic alliances can be a game-changer. Dr. Dupe, a General Practitioner at Christchurch Clinics, and Baba, a Pharmacist at Christchurch Pharmacy, married for 24-years cultivate their synergy through mental wellbeing walks. Their recent 24 kilometres fundraising walk to support a local hospice - Farleigh Hospice, is one of such. Having met Dupe first in 1994, first as interns at a teaching hospital, now married, the couple offer a comprehensive range of services, including pharmacy, private clinics, homecare services as proprietors of Christchurch Health-centre in Braintree. gp; pharmacist; mental wellbeing walks, healthcare Dupe and Baba in their clinic Dr. Dupe and Pharmacist Baba Akomolafe in their clinic, demonstrating their synergy and dedication to patient care. United by faith, a love for healthcare, and a shared commitment to service the community, their 'Mental Wealth Management' as they call it comprises of daily morning walks covering a distance of six kilometres.

Anti-aging expert Darnell Cox knows all about embracing the essence of youth, and credits her ability to do so to her overall mindset and physical well-being. In an exclusive interview, she shares with DynaPro Direct exactly how she gets her head in the game to keep her health at the tippy top of her priority list. Check out her tips and catch some motivation!

Tynor Functional Knee Support is specially designed to support knees which are injured or not working properly due to old age. It stabilizes knees during rotational and anteroposterior forces and cures the ligamentous knee injuries. It provides support to the knees by wrapping around them and thus facilitates their compression. It provides flexibility and easy movement of the knee. It is made of soft, durable fabric which can be stretched in four ways. It mimics the natural knee joint. It can bear the load and shock exerted on it from the external forces leaving the knee totally free from pressure. It contains no buckling or vaso constriction which might hinder comfort. It ensures the proper circulation of blood. It compresses the patellar region and hold it in right position and thus can be used for patellofemoral diseases. It is easy to maintain. Tynor Functional Knee Support Functional knee Support is an anterior opening device, which offers the advantage of controlled compression around the knee and a rigid lateral support and immobilization. It allows normal flexion and free movement of the knee joint. Anterio Open able Easy application Controlled compression. Perfect lateral splinting. Anatomical design. Tynor Functional Knee Support Features Bi axial heavy duty aluminum hinge Mimics the natural knee joint Ensures full weight bearing. Allows free flexion movement Four way stretchable fabric Controlled and comfortable compression No buckling No vaso constriction Enhanced comfort Open patella design Release patellar pressure Hold the patella in position Can be used for Patellofemoral diseases Wrap design with anterior closing Easy application and removal on swollen or asymmetric knees Easy application and removal for weak or geriatric patients. Allows customized compression Offers flexibility in sizing Ergonomic design Anti tourniquet effect - ensures no constriction to blood flow Better grip of the product to the bo

Our organic turmeric toner has a savory, earthy linger. It works as a dark spot remover, giving all skin types a beautiful, luminous complexion. Additionally, it helps with mild skin irritants. Its potent anti-inflammatory and antioxidant properties aid in wound healing while reducing skin irritation. It has a significant amount of antimicrobial ingredients that work to lessen acne and scarring while slowing down free radical damage to skin cells. Use it as a facial toner or activating water in your face masks.

Absolutely! Turmeric toner can indeed be a game-changer for dark spots. Its natural properties, like curcumin, have been shown to help fade hyperpigmentation over time. It's great that you're using it. Remember, consistency is key for noticeable results. Just make sure to patch test first to avoid any allergic reactions. While you buy it at a pharmacy, always check the product's quality and authenticity (so wanna recommend u to do that at Canadian Pharmacy https://www.canadapharmacy.com/ ). Embrace the power of turmeric and enjoy a brighter, more even complexion!

Enterosgel is a versatile safe drug-free alternative to current anti-diarrhoeal medicines found on pharmacy shelves. Enterosgel is different from other anti-diarrhoeals within this category, as it is suitable for children aged one year and over, so can be taken by the whole family. This intestinal adsorbent can be used for both acute diarrhoea due to gastrointestinal infections and for chronic irritable bowel syndrome with diarrhoea (IBS-D). Why should community pharmacists stock this brand? Unlike anti-diarrhoeals which work by slowing gut motility, Enterosgel is an intestinal adsorbent which physically binds harmful substances from the gut, that can cause diarrhoea and other gastrointestinal symptoms and expels them naturally with the stools. Because it is a medical device not a medicine, has no pharmacological action and is not absorbed by the body, it is a safe option for children and adults and can help reduce the likelihood of side effects which can be an issue with anti-diarrhoeal medicines. Enterosgel has a unique composition of an adsorbent mineral gel based in water, it contains no additional preservatives or additives so is easy to recommend from vegetarians to people with allergies or intolerances. The gel is mixed with water and taken orally in between meals; it is tasteless so well tolerated even by children.

In a recent report released by the Company Chemists' Association (CCA), data from the NHS Pharmacy First service indicates a substantial uptake and positive impact on patient care just two months after its launch. The CCA's findings shed light on the service's efficacy in meeting patient needs and its potential to alleviate pressure on General Practices (GPs) within the NHS. According to the report, over 90,000 Pharmacy First consultations were conducted solely by CCA members within the initial two-month period. Impressively, 88 per cent of these consultations, totaling 81,627, were deemed eligible for NHS-funded care indicating a significant demand for the service among patients. In the first month, the data revealed that more than 90 per cent of eligible patients received necessary care directly through Pharmacy First, bypassing the need for further referral.

The Department of Health and Social Care (DHSC), led by Victoria Atkins MP and Maria Caulfield MP, has unveiled proposed updates to the NHS Constitution for England, aiming to fortify the principles of privacy, dignity, and safety for all patients. Martha's rule was prompted by a campaign led by the parents of 13-year-old Martha Mills who tragically succumbed to sepsis after staff at King's College Hospital failed to escalate her care to intensive care, despite her family's pleas regarding her worsening condition in 2021. Under the new guidance is the introduction of Martha's Rule, empowering patients to request intimate care from someone of the same biological sex ensuring that the distinct needs of men and women are recognized and addressed. Patients and their loved ones can exercise the right to "access to a rapid review from outside the care team if the patient is deteriorating." The consultation on the proposed updates is set to run for eight weeks, inviting feedback from patients, healthcare professionals, and stakeholders for a review

In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two groundbreaking formulations of cabotegravir. Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1 infection in adults and adolescents weighing at least 35kg at increased risk. This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or PrEP treatments. HIV, a virus notorious for compromising the immune system, has long been a global health concern. Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus's ability to spread.

The latest formulation of XGEVA (denosumab) is now available to patients in the UK, offering a more convenient treatment option for bone metastasis. It is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP). Denosumab (XGEVA) is used to prevent serious bone-related complications resulting from bone metastasis in adults and to treat giant cell tumour of bone in both adults and adolescents. The medicine was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. In contrast to the current vial presentation, this simplifies the administration process, reducing the volume of liquid injected and lowering the risk of dosing errors. The product was authorised in 30 days by the MHRA, thanks to the new IRP that facilitated a rapid approval process.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Monday (29 January 2024) approved the medicine Rezzayo (rezafungin) to treat invasive candidiasis, an infection caused by a yeast called Candida. Invasive candidiasis can pose a serious health risk as it can affect the blood, heart, brain, eyes, bones and other parts of the body. Napp Pharmaceuticals Ltd was granted the marketing authorisation for the medicine based on phase 3 clinical trial data. In the randomised, double-blind, controlled study, more than half of the invasive candidiasis patients who were given a weekly dose of rezafungin were cured at day 14. Among 94 patients who were given a daily dose of caspofungin (another antifungal treatment), 57 of them were cured during the same time.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio. Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an alternative to surgical castration for locally advanced cases. Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen. The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into its portfolio, aligning closely with Aspire values and therapeutic focus areas. Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per Prostate Cancer UK.

The National Health Services England (NHSE) is poised to revolutionise diabetes management with the introduction of the 'artificial pancreas', also known as the Hybrid Closed Loop system, to treat type 1 diabetes. This pioneering initiative, endorsed by the National Institute of Health Care and Excellence (NICE), represents a global first in healthcare innovation. With 269,095 individuals grappling with type 1 diabetes in England, the Hybrid Closed Loop system is set to cater to tens of thousands of children and adults across the nation. This cutting-edge device operates by seamlessly monitoring blood glucose levels and autonomously adjusting insulin dosage through a pump, by eliminating the need for regular insulin injections. Furthermore, it holds the promise of averting life-threatening hypoglycaemic and hyperglycaemia episodes, mitigating significant risks associated with the condition. To facilitate the identification of beneficiaries, NHSE has allocated a substantial sum of £2.5 million, ensuring that those who could benefit from this innovative solution receive the necessary support.